Search

Author/Creator Minuk, Leonard

1. A multicenter review of infusion-related reactions to daratumumab for relapsed multiple myeloma in the real world setting. (June 2021)

Authors:
Geirnaert, Marc; Howarth, Jacy; Martin, Kristen; Ricard, Chad; Streilein, Scott; Wasney, Danica; Dao, Vi; Kotb, Rami; Rimmer, Emily; Minuk, Leonard
Journal:
Journal of oncology pharmacy practice
Issue:
Volume 27:Number 4(2021)
Page Start:
907
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Issue 6 (June 2022)

Authors:
Dimopoulos, Meletios A; Richardson, Paul G; Bahlis, Nizar J; Grosicki, Sebastian; Cavo, Michele; Beksaç, Meral; Legieć, Wojciech; Liberati, Anna M; Goldschmidt, Hartmut; Belch, Andrew; Magen, Hila; Larocca, Alessandra; Laubach, Jacob P; Petrucci, Maria T; Reece, Donna; White, Darrell; Mateos, Mar...
Journal:
Lancet
Issue:
Volume 9:Issue 6(2022)
Page Start:
e403
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Issue 1 (January 2016)

Authors:
Dimopoulos, Meletios A; Moreau, Philippe; Palumbo, Antonio; Joshua, Douglas; Pour, Ludek; Hájek, Roman; Facon, Thierry; Ludwig, Heinz; Oriol, Albert; Goldschmidt, Hartmut; Rosiñol, Laura; Straub, Jan; Suvorov, Aleksandr; Araujo, Carla; Rimashevskaya, Elena; Pika, Tomas; Gaidano, Gianluca; Weisel,...
Journal:
Lancet oncology
Issue:
Volume 17:Issue 1(2016:Feb.)
Page Start:
27
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Issue 10 (October 2017)

Authors:
Dimopoulos, Meletios A; Goldschmidt, Hartmut; Niesvizky, Ruben; Joshua, Douglas; Chng, Wee-Joo; Oriol, Albert; Orlowski, Robert Z; Ludwig, Heinz; Facon, Thierry; Hajek, Roman; Weisel, Katja; Hungria, Vania; Minuk, Leonard; Feng, Shibao; Zahlten-Kumeli, Anita; Kimball, Amy S; Moreau, Philippe
Journal:
Lancet oncology
Issue:
Volume 18:Issue 10(2017:Oct.)
Page Start:
1327
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Randomized double-blind safety comparison of intravenous iron dextran versus iron sucrose in an adult non-hemodialysis outpatient population: A feasibility study. Issue 1 (December 2016)

Authors:
Louzada, Martha; Hsia, Cyrus; Al-Ani, Fatimah; Ralley, Fiona; Xenocostas, Anargyros; Martin, Janet; Connelly, Sarah; Chin-Yee, Ian; Minuk, Leonard; Lazo-Langner, Alejandro
Journal:
BMC hematology
Issue:
Volume 16:Issue 1(2016)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗